 BOSTON, May 17, 2021 PRNewswire -- NeuroBo Pharmaceuticals, Inc. Nasdaq: NRBO, a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2021. First Quarter Achievements Broadened the potential for product candidate, Gemcabene, by amending its Contingent Value Rights CVR agreement with the holders of the outstanding CVRs, to incentivize the evaluation of Gemcabene as a treatment for COVID-19. 